(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 7.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Biocryst Pharmaceuticals's revenue in 2025 is $599,816,000.On average, 13 Wall Street analysts forecast BCRX's revenue for 2025 to be $133,040,157,813, with the lowest BCRX revenue forecast at $126,502,790,708, and the highest BCRX revenue forecast at $138,017,399,629. On average, 13 Wall Street analysts forecast BCRX's revenue for 2026 to be $143,299,929,119, with the lowest BCRX revenue forecast at $129,164,057,060, and the highest BCRX revenue forecast at $152,856,486,056.
In 2027, BCRX is forecast to generate $157,505,280,442 in revenue, with the lowest revenue forecast at $136,592,022,002 and the highest revenue forecast at $171,175,851,976.